MedTrace Logo

Oral FMT (Fecal Microbial Transplant) in Subjects with Multiple Sclerosis

NCT04096443 · Status: ACTIVE_NOT_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2024-10-18

No results posted yet for this study

Summary

The goal of this pilot study is to determine whether fecal microbial transplant (FMT) has the potential to be an effective, safe and tolerable therapy for the treatment of multiple sclerosis (MS). The investigators plan to gather preliminary data in a small cohort of 10 to 15 adults with MS.

Conditions

Interventions

BIOLOGICAL

Fecal microbial transplant (FMT)

Oral fecal microbial transplant capsules

Sponsors & Collaborators

  • Yale-Griffin Prevention Research Center

    collaborator OTHER

  • Griffin Hospital

    lead OTHER

Principal Investigators

  • Joseph B Guarnaccia, MD · Griffin Hospital

  • Frederick Browne, MD · Griffin Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-28
Primary Completion
2023-09-21
Completion
2024-12-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04096443 on ClinicalTrials.gov